PHILADELPHIA, March 18, 2019 /PRNewswire/ -- At Pittcon
2019, Bruker (Nasdaq: BRKR) this week highlights new and innovative
analytical systems and high-value applied market solutions for food
analysis, pharma applications, materials science research and
quality control, clinical and preclinical research, and advances in
scientific software solutions.
Frank H. Laukien, Ph.D., Bruker's
President and CEO, commented: "Our new analytical instruments
and solutions shown at Pittcon 2019 demonstrate the diversity and
flexibility that Bruker brings to the world of laboratory science.
Bruker is committed to providing the best technological solutions
to meet the analytical requirements of our customers, and that
includes increasing our presence in the laboratory software and
applied solutions markets."
Applied and Industrial R&D and QC
The novel INVENIO-S FTIR system is the entry-level
version of the flexible and innovative INVENIO®
platform, replacing the very successful TENSOR FTIR series. The
INVENIO-S is a new, high-performance FTIR
spectrometer focused on maximum productivity in advanced laboratory
analysis and research. Bruker's permanently aligned
RockSolidTM
interferometerCenterGlowTM IR source,
temperature controlled DTGS, and the long-life diode laser together
ensure best performance, robustness and low running costs.
The integrated touch panel operation provides intuitive guidance
with typical workflows from routine analytical QC protocols to
R&D applications.
The new G6 LEONARDOTM is an economic,
robust and precise inert gas fusion (IGF) analyzer for oxygen,
nitrogen and hydrogen (ONH) concentration measurements in inorganic
samples. The G6 LEONARDO introduces SampleCare ™ into
IGF-analysis for metals and ceramics, and deploys the Smart
Molecule SequenceTM for elemental analysis. With
its pre-calibrated standard methods and argon gas instead of
helium, the G6 LEONARDO addresses the needs of industrial process
and QC for easy and cost-effective operation.
Laboratory Software and Solutions for Pharma
Bruker announced that it has acquired Arxspan LLC
, a provider of cloud-based scientific software and workflow
solutions. Arxspan is known for its line of cloud-based products
for the management of research data, with a focus on serving
pharmaceutical and biopharma customers. Bruker can now
provide a range of software tools for customers in the chemistry,
pharmaceutical, biopharma and analytical laboratory markets.
Together with the Mestrelab strategic partnership and majority
investment, the acquisition of Arxspan will allow Bruker to offer
state-of-the-art chemistry and biopharma software tools, supporting
discovery and development.
Bruker and Mestrelab Expand Software Solutions
Portfolio for applied NMR: The laboratory of tomorrow
requires the integration of multiple technology platforms. The
strategic collaboration of Mestrelab and Bruker is expected to
provide a simple, instrument-to-result automation environment that
allows users to build automated solutions tailored to their
workflow. An example is the integration of Bruker's
Fragment-Based Screening (FBS) solution with
Mestrelab's MScreen software, which
provides drug discovery groups with an integrated experience from
data acquisition and data analysis to the identification of hits in
FBS-by-NMR campaigns.
Bruker also announces minispec Form
Check, a reliable and affordable TD-NMR
(Time-Domain Nuclear Magnetic Resonance) solution to monitor phase
purity and quantify physical API (Active Pharmaceutical Ingredient)
forms including amorphization. The patent pending minispec
Form Check uses 1H or 19F relaxometry data as
easy-to-obtain fingerprints for expected components in solid
mixtures, replacing excessive calibration, delicate sample
preparation and expert know-how. In the pharma industry, API
form characterization and quantification are important from drug
development and formulation to manufacturing, where it is important
to understand how solid API forms are influenced by production and
storage.
Quantitative Performance Qualification (qPQ) for Quantitative
NMR (qNMR) Applications: A collaboration between Bruker
and MilliporeSigma has led to the development of certified
reference materials (CRM) tailored to qNMR. A novel, two-component
mixture manufactured in the ISO/IEC 17025 and ISO 17034
accreditated workflow at MilliporeSigma is the basis of the new qPQ
test. This qPQ is now incorporated within the Bruker
AssureSST™ software, allowing automated PQ tailored to
qNMR.
Food Analysis Solutions
Bruker announced the launch of the MIRA milk
analyzer based on infrared technology, as well as the
GLOBULYSER for analyzing the homogenizer efficiency
of raw milk and liquid milk products. The
MIRA features ease-of-use in a high precision
analyzer with IR technology. MIRA is a robust,
cost-effective solution for QC of raw milk, processed or
standardized milk, whey and cream. The GLOBULYSER has
been developed in cooperation with the dairy industry to create an
easy-to-use analyzer for mean fat globule size in milk, liquid milk
products, and in dissolved milk powders.
The new, proprietary Honey-Profiling 2.0
Method for the Bruker NMR
FoodScreener® platform now further improves the
detection of sugar syrups, and considerably expands the scope of
geographical and botanical honey origins that can be verified,
including the popular manuka honey which is subject to frequent
fraud due to its high value. The expanded 2.0 method was developed
in collaboration with partners QSI and Alnumed, and features a
reference database containing over 18,000 honey samples, 50
geographical origins and 100 botantical varieties. With
Honey-Profiling 2.0, a
comprehensive analysis of authenticity and quality is performed
under automation in 25 minutes.
Clinical Phenomics and Proteomics
Bruker and Murdoch University have announced a collaboration for
a phenomics center of excellence in Australia to further develop NMR and
MS-based Precision Medicine Solutions. Murdoch
University (www.murdoch.edu.au), the Australian National
Phenome Center (ANPC, a core platform of the Western Australian
Health Translation Network) and Bruker announced a memorandum of
understanding for a metabolomics research and instrumentation
infrastructure collaboration to develop the world's premier
phenomics center for the advancement of precision medicine.
Jeremy Nicholson, Ph.D.,
ProVice Chancellor of Health Sciences at Murdoch University and
leading the APCN, commented: "This collaboration brings
state-of-the-art instruments and experienced professionals to
Australia, augmenting the growing
investment in precision medicine in the Asia Pacific region. Working with Bruker the
ANPC at Murdoch aspire to create new disease prevention and
treatment strategies through integrative studies of humans in their
total environment. This will enable better understanding of gene-
environment interactions that determine health status of
individuals and populations. We wish to leverage key technology
advantages offered by Bruker platforms and address new challenges
that link precision nutrition and health programs to large scale
food screening and population phenotyping. Such precise data will
allow clinicians to better predict health problems and intervene
earlier, saving time, money and lives. The potential of this
research to provide truly personalized care is remarkable."
Microscopy, Preclinical Imaging and Nanoanalysis
The new SKYSCANTM 1273 3D X-ray
microscope (XRM) sets a new standard for high-resolution
non-destructive testing (NDT) with benchtop microCT systems with
performance previously only achieved by floor standing systems.
Samples with up to 20kg weight and up to 500 mm length and 300 mm
diameter can be investigated. The combination of an innovative
X-ray source running at higher power settings and a 6-megapixel
flat-panel detector with high sensitivity and speed provides
excellent image quality in seconds. Areas of application
range from manufacturing, geology, oil and gas exploration to bone
imaging.
Bruker announces an order from the Champalimaud Foundation in
Portgual for the world's first, preclinical
BioSpec® 18 Tesla
ultra-high field magnetic resonance imaging (MRI) system
for delivery in 2021. The ultra-high magnetic field and
sensitivity-enhancing CryoProbes will be used to develop novel
contrasts in MRI and MR spectroscopic imaging. These new methods
will be applied to investigate cancer, metastasis and premetastatic
niches in vivo in multiple animal models of cancer; as well
as for advanced neuroscience research on mouse brain plasticity and
activity. The novel MRI system will enable truly microscopic 3D
spatial resolution in vivo, allowing very detailed
morphology investigations.
The JPK NanoWizard® ULTRA Speed 2
combines high speed and resolution AFM with advanced bio-imaging
features. Developed in close collaboration with bio-AFM customers,
the system is the first new product to come out of Bruker's JPK
BioAFM business, formed in July 2018
with the acquisition of JPK Instruments AG. With an AFM scanning
speed of 10 frames per second, true atomic resolution and advanced
life-science capabilities, it raises the bar in technical
performance for correlative microscopy applications.
The new Dimension XR™ family of scanning probe
microscopes incorporate major AFM innovations, including Bruker's
proprietary and exclusive DataCube nanoelectrical modes, AFM-SECM
for energy research, and the new AFM-nDMA mode, which
for the first time correlates polymer nanomechanics to bulk dynamic
mechanical analysis (DMA). Dimension XR is available in three
configurations optimized for nanomechanics, nanoelectrical or
nanoelectrochemical applications. These systems significantly
expand researchers' ability to quantify material properties at the
nanoscale in air, fluids, electrical and chemically reactive
environments.
Please join us at Bruker's Pittcon booth # 2754 throughout the
conference, and at our press conference on Tuesday, March 19, 2019, at 10:30 am to 11:30 am EDT at the Pennsylvania Convention Center, Room
Banquet – 204 A. For more information on Bruker at Pittcon 2019:
https://www.bruker.com/events/mr/pittcon-2017.html https://www.bruker.com/events/pittcon/press-conference
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker's high-performance scientific instruments and
high-value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular research, in applied and pharma applications, in
microscopy and nanoanalysis, and in industrial applications, as
well as in cell biology, preclinical imaging, clinical phenomics
and proteomics research and clinical microbiology. For more
information, please visit: www.bruker.com.
Investor Contact:
Miroslava
Minkova
Director, Investor Relations & Corporate Development
T: +1 (978) 663-3660 x1479
E: miroslava.minkova@bruker.com
Media Contact:
Thorsten
Thiel, Ph.D.
VP of Group Marketing
T: +49 (721) 5161–6500
E: thorsten.thiel@bruker.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/bruker-highlights-new-systems-and-applied-market-solutions-at-pittcon-300813751.html
SOURCE Bruker Corporation